Nanoemulsion as an Effective Inhibitor of Biofilm-forming Bacterial Associated Drug Resistance: An Insight into COVID Based Nosocomial Infections

Deena Santhana Raj, Duraisami Dhamodharan, Thanigaivel S, Vickram A S, and Hun-Soo Byun

Received: 23 February 2022 / Revised: 30 March 2022 / Accepted: 6 April 2022 © The Korean Society for Biotechnology and Bioengineering and Springer 2022

Abstract Antibiotic overuse has resulted in the micro-evolution of drug-tolerant bacteria. Understandably it has become one of the most significant obstacles of the current century for scientists and researchers to overcome. Bacteria have a tendency to form biofilm as a survival mechanism. Biofilm producing microorganism become far more resistant to antimicrobial agents and their tolerance to drugs also increases. Prevention of biofilm development and curbing the virulence factors of these multi drug resistant or tolerant bacterial pathogens is a newly recognised tactic for overcoming the challenges associated with such bacterial infections and has become a niche to be addressed. In order to inhibit virulence and biofilm from planktonic bacteria such as, Pseudomonas aeruginosa, Acinetobacter baumannii, and others, stable nanoemulsions (NEs) of essential oils (EOs) and their bioactive compounds prove to be an interesting solution. These NEs demonstrated significantly greater anti-biofilm and anti-virulence activity than commercial antibiotics. The EO reduces disease-causing gene expression, which is required for pathogenicity, biofilm formation and attachment to the surfaces. Essential NE and NE-loaded hydrogel surface coatings demonstrates superior antibiofilm activity which can be employed in healthcare-related equipments like glass, plastic, and metal chairs, hospital beds, ventilators, catheters, and tools used in intensive care units. Thus, anti-virulence and anti-biofilm forming strategies based on NEs-loaded hydrogel may be used as coatings to combat biofilm-mediated infection on solid surfaces.

Keywords: drug-resistant bacteria, microevolution, COVID-19, nanoemulsions, anti-biofilm, essential oils

1. Introduction

With the discovery of antibiotics like penicillin in the early nineteen twenties and the multitude of antibiotics being commercialised since then, a notion of all cures has been taken for granted. The use of these on a large scale has led to the microevolution of multidrug-resistant bacteria. The development of resistance or tolerance to any therapeutic agent compromises the successful use of that particular drug from the very first time of its use. This stands true for any treatment whether bacterial, fungal, parasitic, or even viral infection. Various physiological or biochemical mechanisms could be responsible for the growing tolerance. Specifically, in regards to antimicrobial agents, lack of adequate knowledge and the complexity of the process of developing tolerance itself are leading causes that there has been no significant accomplishment in preventing or controlling drug resistance. There are several recommendations in literature advocating resolutions but to no avail. The microevolution of drug resistance is inevitable [1]. Some bacterial strains are now resistant to essentially all commonly available antibiotics, for a case, methicillin resistant Staphylococcus aureus, has developed tolerance to not only methicillin but also various agents like macrolides, aminoglycosides, lincomamides and chloramphenicol and some kinds of disinfectants. Such strain that become
resistant to even disinfectants contribute a majority of source for nosocomial infections also known as hospital acquired infections (HAIs), the overall schematic of the biofilm forming bacteria and its inhibitory mechanism using nanoemulsion (NE) is demonstrated in the Fig. 1. [2]. This raising concern affects not only humans in general but also animal care and health care industry as a whole.

An even more deadly threat could be considered as the emergence of Gram-negative pathogens that tolerate almost all of the available antimicrobial agents. “Pan-resistant” a term relating to resistance developed for all available antimicrobial agent [3], particularly belonging to the strains Pseudomonas aeruginosa and Acinetobacter baumannii, [4] are now causing a high concern in recent times owing to that fact that pharmaceutical industries have not developed any new generation antibacterial agent that is effective against these strains, which have a low permeable barrier in the outer membrane and a range of efficient multidrug-resistant efflux pumps that work in sync with scores of specific resistance mechanisms. According to World Health Organization (WHO) reports [5], nosocomial infections affects a vast number of patients worldwide with great mortality rate and cause significant economic disturbance.

In a prevalence survey undertaken by WHO in fifty-five hospitals in panning over 14 countries showed an average 8.7% of hospitalized patients readmitted due to nosocomial infection [6]. Approximately 15% of all patients who are hospitalised get readmitted with these infections. Neonatal cases have upto 18% mortality rate [7]. The occurrences of overall such infections in developing countries is three times higher than in developed countries [8].

2. Burdens of Nosocomial Infections

The major types of nosocomial infection include Catheter-Associated Urinary Tract Infections (CAUTI), infections associated with bloodstream and the central line (CLABSI), pneumonia infection associated with ventilators (VAP), and surgical site infections (SSI) [9].

2.1. Central line associated bloodstream infections

CLABSI are lethal nosocomial infections with mortality rates of 12% to 25%. Catheters are inserted into the intravenous lines near the centre of the body to provide fluid and medicines, but prolonged use causes serious bloodstream infections which can result in compromised health and in some cases even death [9].

2.2. Catheters-associated urinary tract infection

CAUTI is one of the frequently occurring nosocomial infections globally. They are primarily caused by endogenous microflora of the patients. Catheters placed inside the urinary tract serve as an entry point of bacteria and imperfectly drained catheters retain some number of bacteria which provides a very conducive environment for the bacteria to thrive. CAUTI can lead to severe complications like epididymitis, prostatitis, cystitis, meningitis leading to mortality.
2.3. Surgical site infection
Surgical site infections are found in 2% to 5% of patients who have undergone surgeries. These are also one of the most commonly acquired nosocomial infections primarily caused by *S. aureus* which can cause compromised health leading to prolonged hospitalisation or in some cases death. These also arise from the endogenous microflora of patients [10].

2.4. Ventilator associated pneumonia
VAP accounts for 9% to 27% of HAIs in patients who are mechanically assisted in breathing using ventilators. It is usually detected within 48 h of tracheal intubation. Close to 90% of nosocomial pneumonia is related to ventilator use. Commonly found symptoms of VAP include raging fever, leukopenia, and wheezing sounds.

3. Emergence of Opportunistic Pathogens
The wake of the emerging pandemic COVID-19, a novel SARS-CoV-2 Coronavirus, brought devastation on a global scale, multitudes of people were hospitalised and treated and with this, the uproar of HAIs was also heard even louder. The viral respiratory infections predisposes patients with bacterial infections, these co infections were using spread through the use of contaminated glass, plastic, and metal chairs, hospital beds, ventilators, catheters, and COVID emergency tools used in intensive care units (ICUs) in a retrospective study [10], it was found that in ICUs almost all the microbiological investigations conducted in COVID-19 related cases, 28% of bacterial coinfection rates, that is, the patients were simultaneously infected by other pathogens like *S. aureus*, *Enterobacteriaceae*, *Streptococcus pneumoniae*, and *Haemophilus influenzae*.

These categorical pathogens promote virulence and evade the already compromised immune response of the host by producing biofilm, and by inducing virulence factors like hemolysins, adhesins cytokines, pneumolysin and acquisition of iron from host, besides other virulence factors of particular interest is biofilm formation as shown in Fig. 2. Prevention of biofilm from forming and curbing the virulence factors of pathogenic bacteria is a newly recognised tactic for addressing the challenges associated with bacterial infections.

3.1. Complex mechanism of biofilm formation
Biofilm is a complex syntropic consortium of the planktonic bacteria [11]. They form colonies within an extracellular matrix which is composed of environmental DNA, polysaccharides, extracellular polymeric substance and some protein produced by the consortium. The microbial cells adhere to each other and onto a living or non-living static surface. Biofilms of bacteria being pathogenic, in the scenario of healthcare environment causes nosocomial infections.

The National Institute of Health confers the formation of complex biofilms are related to 80% of the chronic infections. There are many steps involved in the formation of biofilm. It starts with the adherence to a static surface which then leads to the formation of a micro-colony. These microcolonies form three dimensional structures and finally detach themselves after maturation as visualised. During this process, several bacterial species are found to communicate among themselves using quorum sensing. These biofilms essentially make the bacteria highly resistant to the antibiotics the human immune system as well as disinfectants, this causes great concern over surface related and medical device related infections in the case of immunocompromised individuals such as COVID-19 patients.

Prevention of biofilm from forming and restriction of the virulence factors of bacterial pathogens is a newly recognised tactic for addressing the challenges associated with bacterial infections and thus it is of utmost importance that new agents with anti-biofilm activities are employed for such tasks.

In this regard, nanotechnology provides a viable solution by providing targeted drug delivery, which enhances the effectiveness of therapeutic agents and the provides protection

---

Fig. 2. General overview of nanoemulsion formulation.
to medical devices against biofouling. The emerging concept of green nanotechnology has provided a paradigm shift in development of eco-friendly, non-hazardous and highly efficient nanomaterials which proves to be an armoured asset in the battle against nosocomial infections [12,13].

Table 1 consists of conventional antibiotics currently used for the inhibition of biofilms, although in some cases they are effective, bacteria soon become resistant and in an attempt to reduce harsh harmful chemicals, green alternative therapeutic agents have been studied extensively [14-19]. It is of common knowledge since age untold that, medicinal and aromatic plants (MAPs) have antimicrobial properties, thus inclining towards them only seems like the natural course [20-24].

Oils from these MAPs are essential oils (EOs) that are obtained from MAPs are highly aromatic due to the presence of multifarious chemical substances such as terpenes, phenols, aldehydes, ketones, ethers and alcohols [25,26]. EOs in MAPs are mostly accumulated in the secretory cavities or canals, in their epidermal cells and in their glandular trichomes [27].

The chemical constituents of the EOs exhibit more bioactivity when they are exposed to oxygenated form as they become more bioactive. The biochemical composition of EOs is very complex and they have about 20 to 60 different bioactive components. Monolaurin with Tween 20 and Tween 80 and Tween 40 have been reported to be up to 92% inhibition in diluted NE and undiluted NE completely inhibits S. aureus and Escherichia coli cells in under 1 min [28].

Table 2 summarizes some MAPs with their bioactive agents and the bacterial strains they are effective against [29-98]. The most common methods of extraction are steam distillation, cold press extraction, carbon dioxide extraction, solvent extraction, water distillation, and enfleurage, maceration. Out of these methods suitable methods can be selected for the particular EO based on the part of the plant used, for instance, the cold press methods are best suited for extraction of oils from citrus peels as the peels need to be pierced and squeezed.

In order to enhance and to augment the efficiency of these EOs, complexing it with more advanced nanotechnology accentuates the anti-biofilm activity of these EOs. But the constraints and limitation arise due to the rapid releasing of

| Antibiotics | Species | Consequence on bacterial biofilm | References |
|-------------|---------|---------------------------------|------------|
| B-Lactams   | Methicillin resistant Staphylococcus aureus | Anti-biofilm activity per subsequent exposure and induction of biofilm formation at subinhibitory concentrations | [14] |
| Ciprofloxacin | Escherichia coli | Inhibited the forming of biofilm expression levels of the virulence genes were also suppressed | [15] |
| Rifampicin | Pseudomonas aeruginosa | Unaided antibiofilm activity or synergistically with other agents | [16] |
| Vancomycin | Staphylococcus aureus | Inhibiting release of eDNA at subinhibitory concentrations leading to decrease in biofilm formation | [17] |
| Daptomycin | Staphylococcus epidermidis | Anti-biofilm effect by penetrating cluster and decrease the viability | [18] |
| Fosfomycin | Escherichia coli | Anti-biofilm activity per subsequent exposure and induction of biofilm formation at subinhibitory concentrations synergistically with other agents | [19] |

**Table 2.** Various essential oils, their bioactive chemical constituents, and its antibacterial activity

| Medicinal and aromatic plants | Inhibited bacterial species | Bioactive chemical constituents | References |
|------------------------------|-----------------------------|--------------------------------|------------|
| Achillea claverna | Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Pseudomonas aeruginosa | Camphor, 1,8-cineole, geranyl acetate, β-caryophyllene, linalool, myrcene | [29] |
| Achillea fragrantissima | Staphylococcus aureus, Escherichia coli, Staphylococcus epidermidis | Thujone, 1,8-cineole, artemisia alcohol, Yomogi alcohol | [30] |
| Artemisia absinthium | S. aureus, E. coli, S. epidermidis | Myrcene, transsabinyl acetate, transthujone | [31] |
| Artemisia biennis | S. aureus, E. coli, S. epidermidis | Derivatives of beta-farnesene, beta-oicimene, acetylenes, En-yn-dicycloether | [31] |
| Artemisia cana | S. aureus, E. coli, S. epidermidis | Santolina triene, camphene, alpha-pinene | [31] |
| Artemisia dracunculus | S. aureus, E. coli, S. epidermidis, Brochothrix thermosphaeta, Listeria innocua, Shewanella putrefaciens | Methylchavicol, terpinolene, beta-phellandrene, methyl eugenol | [31,32] |
| Artemisia longifolia | S. aureus, E. coli, S. epidermidis | Camphene, Alpha-pinene, 1,8-cineole | [31] |
| Artemisia frigida | S. aureus, E. coli, S. epidermidis | 1,8-Cineole, camphor, methylchavicol | [33,34] |
Table 2. Continued

| Medicinal and aromatic plants | Inhibited bacterial species | Bioactive chemical constituents | References |
|------------------------------|----------------------------|-------------------------------|------------|
| **Cinnamomum zeylanicum**    | Enterobacteriaceae, S. aureus, E. coli, S. epidermidis, Staphylococcus pyogenes, Enterococcus faecalis, Escherichia faecium, Bacillus cereus, Enterococcus spp. | Cinnamaldehyde | [35,36] |
| **Copaifera officinalis**    | S. aureus, E. coli, K. pneumoniae, P. aeruginosa | δ-cadinene, β-Caryophyllene, β-bisabolene, germacrene B, α-copaene, α-humulene, germacrene D | [37] |
| **Coriandrum sativum**       | Salmonella typhi, Bacillus subtilis, S. aureus, E. coli | 2E-Decenal, n-decanol, decanal, 2E-decen-1-ol | [38,39] |
| **Cuminum cyminum**          | Salmonella typhimurium, S. aureus, E. coli | Cuminaldehyde, γ-terpinene, γ-terpin-7-al, β-pinene | [40] |
| **Cyperus longus**           | S. aureus, E. coli, Listeria monocytogenes, Enterococcus faecium, Salmonella enteritidis, P. aeruginosa | α-humulene, β-Himachalene, γ-himachalene | [41] |
| **Daucus littoralis**         | S. aureus, E. coli | Germacrene D, acorenone B | [42] |
| **Dracocephalum foetidum**   | Micrococcus luteus, Enterococcus hirae, Staphylococcus mutans, S. aureus, E. coli, B. subtilis | Geranial, 8-dien-10-ol, n-Mentha-1, limonene | [43-45] |
| **Eremanthus erythropappus**  | S. epidermidis | Caryophyllene, γ-terpinene, germacrene D, p-cymene, viridiflorol | [46] |
| **Eugenia caryophyllata**    | S. epidermidis | Phenylpropanoids, cinnamaldehyde, eugenol, carvacrol, thymol | [47] |
| **Euphrasia rostkoviana**    | E. coli, K. pneumoniae, S. aureus, S. epidermidis, S. epidermidis, E. faecalis, P. aeruginosa | Thymol, myristic acid, linalool, n-Hexadecanoic acid | [48] |
| **Eucalyptus**               | S. typhimurium, E. coli | Trans-anethole, methylchavicol, limonene | [49] |
| **Fortunella margarita**     | S. aureus, B. subtilis, S. faecalis, Sarcina lutea, E. coli, K. pneumoniae, P. aeruginosa | Gurjunene, eudesmol, murolene | [49,50] |
| **Juniperus phoenicea**      | L. monocytogenes, E. faecalis, E. coli, S. aureus | α-Pinene, β-phellandrene, α-terpinyl acetate | [41] |
| **Laurus nobilis**           | Mycobacterium smegmatis, E. coli | Eucalyptol (1,8-cineole), linalool | [41,51,52] |
| **Lavandula x intermedia**   | M. smegmatis, E. coli | Camphor, α-pinene, eucalyptol (1,8-cineole), linalool, β-pinene | [53] |
| **Juniperus excelsa**        | S. aureus | α-Pinene, α-cedrol, δ-car-3-ene | [54,55] |
| **Lippia sidoides**          | Streptococcus mutans, Streptococcus sanguis, Streptococcus mitis, Streptococcus salivarius | Thymol and carvacrol | [56,57] |
| **Mentha pulegium**          | E. faecium, S. epidermidis, B. cereus, S. enteritidis, S. aureus, L. monocytogenes, Vibrio cholerae, E. coli, S. typhimurium | Piperitenone, pulegone, α-terpineol, Piperitone | [41] |
| **Mentha suaveolens**        | Lactococcus lactis | Piperidones, cis-cis-p-methenolide, Pulegone, limonene germacrene | [58-60] |
| **Melaleuca alternifolia (tea tree oil)** | E. coli, E. faecalis, S. pyogenes, S. aureus, S. epidermidis, S. pneumonia, H. influenzae, P. aeruginosa, Mycobacterium avium | Terpinen-4-ol, terpinolene, 1,8-cineole, α-terpinene, γ-terpinene | [61-64] |
| **Monarda charantia**        | S. aureus, E. coli | Apiole, Trans-nerolidol, cis-dihydrocarve, ol germacrene D | [65] |
| **Myrtus communis**          | B. subtilis, K. pneumoniae, subsp. paratuberculosis, P. aeruginosa, S. typhi, Enterobacter cloacae, Mycobacterium tuberculosis, Enterococcus durans, E. coli, S. aureus, M. avium, L. monocytogenes | α-terpineol, γ-terpineine, eugenol | [66,67] |
| **Nigella sativa**           | P. aeruginosa, B. cereus, S. aureus, E. coli | Thymoquinone, longifolene, p-cymene, thymohydroquinone, α-thujene | [68-70] |
| **Ocimum gratissimum**       | S. typhi, S. aureus, P. aeruginosa, Bacillus spp., Proteus mirabilis, K. pneumoniae, E. coli, E. cloacae | Eugenol, cis-coumarone, trans-coumarone, methyl eugenol, α-pinene, camphor | [71,72] |
| Medicinal and aromatic plants | Inhibited bacterial species | Bioactive chemical constituents | References |
|-------------------------------|-----------------------------|-------------------------------|------------|
| Ocimum klimanscharicum        | *E. coli*, *B. subtilis*, *Klebsiella spp.*, *S. aureus*, *Proteus spp.*, *Citrobacter youngei*, *Pseudomonas spp.*, *Micrococcus spp.*, *Salmonella spp.* | Eugenol, borneol, linalool, methyl eugenol | [73] |
| Ocimum basilicum              | *B. thermosphacta*, *E. coli*, *L. monocytogenes*, *L. innocua*, *S. typhimurium*, *Micrococcus flavus*, *Pseudomonas putida*, *S. putrefaciens* | γ-Terpinene, methylchavicol | [73-75] |
| Petroselinum sativum          | *S. putrefaciens*, *S. typhimurium*, *L. innocua*, *E. coli*, *P. putida*, *B. thermosphacta*, *L. monocytogenes* | 1,4-tetramethoxy-5-(2-propenyl)-benzene, Paracymene, linalool, terpinen-4-ol, camphene, α-copaene, eugenol, 1,8 cineole, α-pinene, β-caryophyllene, Limonene, δ-3-carene, α-felandeno, myrcene, β-pinene, sabine, safrole, terpinolene, β-selinene, α-terpinene, α-humulene | [23] |
| Piper nigrum                  | *S. aureus*, *E. coli* | Trans-anethole | [78-80] |
| Pimpinella anisum             | *S. tsyphimurium*, *E. coli* | α-Pine, trans-caryophyllene, β-pinene, Caryophyllene oxide | [81] |
| Plectranthus neochilus         | *S. mitis*, *Streptococcus sobrinus*, *E. faecalis*, *Streptococcus sanguinis*, *Listeria casei*, *S. mutans*, *S. salivarius* | δ-guaieno; gurjunene-α, α-guaiene, aromadendrene, β-patchoulene, Patchoulol | [82] |
| Pogostemon cabilin            | *K. pneumonia*, *E. faecalis*, *P. aeruginosa*, *Helicobacter pylori*, *E. coli*, *B. subtilis*, *S. aureus* | Camphor, camphene, limonene, geranel, myrcene, linalool benzoylacetate, linalool, α-pinene, α-terpinolene, bornyl acetate, linalool | [83,84] |
| Rosmarinus officinalis         | *Streptococcus agalactiae*, *S. putrefaciens*, *L. innocua*, *E. faecalis*, *P. putida*, *L. monocytogenes*, *B. subtilis*, *S. typhimurium*, *P. aeruginosa*, *Proteus vulgaris*, *B. thermosphacta*, *K. pneumonia*, *B. cereus*, *M. smegmatis*, *S. aureus*, *E. coli*, *S. typhimurium*, *S. epidermidis* | β-ocimene acetate, Linalool, Caryophyllene oxide, linalyl acetate, Geranyl acetate | [85,86] |
| Salvia scarea                  | *S. agalactiae*, *S. epidermis*, *E. faecalis*, *B. subtilis*, *K. pneumonia*, *P. aeruginosa*, *Bacillus pumilus*, *S. typhimurium*, *S. aureus*, *P. vulgaris*, *E. coli* | 1,8-cineole, α-pinene, α-Thujone, camphor | [87,88] |
| Salvia officinalis             | *Shigella sonnei*, *S. aureus*, *Providencia stuartii*, *E. coli*, *L. innocua*, *M. flavaus*, *B. thermosphacta*, *L. monocytogenes*, *S. lutea* | Camphor, beta-thujone, α-thujone, camphene, terpinolene, α-pinene | [89] |
| Salvia lavandulifolia          | *P. vulgaris*, *E. faecalis*, *P. aeruginosa*, *K. pneumonia* | Carvacrol and p-cymene | [90,91] |
| Satureja cuneifolia            | *E. coli*, *S. enteritis*, *Campylobacter jejuni*, *S. sonnei*, *P. aeruginosa*, *B. cereus*, *S. aureus*, *L. monocytogenes* | Camphor, beta-thujone, α-thujone, camphene, terpinolene, α-pinene | [92] |
| Struchium sparganophora        | *B. cereus*, *S. typhi*, *P. aeruginosa*, *P. mirabilis*, *B. subtilis* | β-Caryophyllene, germacrene A, α-humulene, germacrene D | [93] |
| Syzygium cumini                | *P. aeruginosa*, *S. aureus*, *Neisseria gonorrhoeae*, *E. coli*, *S. aureus*, *B. subtilis* | α-caryophyllene, α-limonene 1,3,6-octatriene, delta-3-carene, trans-caryophyllene, α-Pine, β-pinene | [94] |
| Thymus vulgaris                | *S. putrefaciens*, *Clostridium botulinum*, *E. coli*, *S. typhimurium*, *S. sonnei*, *S. lutea*, *S. aureus*, *M. flavaus*, *L. monocytogenes*, *B. thermosphacta*, *S. typhimurium*, *L. perfringens*, *L. monocytogenes*, *P. putida* | Camphene, α-pine, borneol, β-pinene eugenol, camphor, carvacrol, 1,8-cineole, thymol, linalool | [95,96] |
| Thymus kotschyanus             | *S. aureus*, *B. cereus*, *S. epidermidis*, *E. coli* | 1,8 cineole, borneol, E-caryophyllene, thymol | [97] |
| Verbena officinalis            | *E. coli*, *S. aureus*, *L. monocytogenes*, *S. typhimurium* | Borneol, geraniol | [98] |
| Warionia saharae               | *E. coli*, *P. aeruginosa*, *B. cereus*, *S. aureus* | β-Eudesmol, linalool, 1,8 cineole, trans-nerylodol, p-cymene, terpinen-4-ol, camphor | [99] |
the bioactive compounds to the surface, the oxidation of EO due to environmental conditions and a considerable change in the biological activity.

### 3.2. Intervention of nanoemulsion based strategies to overcome resistance

Nanomaterials are being exploited as efficient carriers to deliver lipophilic drugs and bioactive molecules [99-103]. There are many advantages of going nano for drug delivery such as controlled drug release, enhanced drug solubility, improved biocompatibility and bioavailability, augmented therapeutic index, extended therapeutic effects, decreased systemic toxicity and control of increase in drug resistance. According to the recent trends, metal oxide and metal nanoparticles such as gold nanoparticles, silver nanoparticles, zinc oxide nanoparticles have found a solid ground as antimicrobial agents by specifically targeting the quorum sensing regulated pathogenesis and biofilm formation [104-107]. Emerging findings suggest a more biocompatible and enhanced stable polymeric nanoparticles which aids in encapsulation of bioactive materials which can downregulate the quorum sensing and thus effectively prevent biofilm formation [108]. NEs are novel exciting vehicles for delivering EOs for combating biofilm formation because of their many favourable properties such as thermodynamically stability and kinetic stability [109-111]. Unlike antibiotics, the antimicrobial activities of NEs are nonspecific, which makes them excellent tools for broad spectrum activity for wound treatment as well as surface decontamination and further dissipate the possibilities of development of resistance.

NEs is defined as heterogeneous system where one liquid is dispersed into another as nano droplets in the while an emulsifying agent is present [112] which mediated the amalgamation of two immiscible liquids in a micellar solution, under highly controlled conditions as the physicochemical properties of NEs are easily influenced by qualitative and quantitative compositions of both liquid and they are predominantly made in the size range of 20 to 200 nm, which makes it more suitable for the various application based on properties listed in Fig. 1.

There are two types of NEs, oil in water (O/W) and water in oil. Out of these, O/W type of NE are preferred due to its potential to solubilize and encapsulate large quantities of EOs and protect them from hydrolysis, evaporation and from drying out. The base capsules of these NEs are mostly hydrogels, as they can be fabricated using natural or synthetic polymers with three-dimensional network structure with very high-water content. It is highly biocompatible, adheres to surfaces easily which makes them ideal in the form of surface coatings to prevent biofilm formation [113-115].

Various methods of preparation of NEs have been reported, and these can be categorized into two main divisions: high energy and low energy based on the extent of external energy provided [116,117].

The high energy method utilizes a mechanical device to generate high energy such as homogenizers, ultrasonicator, microfluidizers, and high-pressure homogenizer. These devices disrupt the dispersed phase and convert them into tiny NEs. High pressure valve homogenizer generates pressure of up to 350 MPa in the chamber and factors such as shear stress, cavitation, turbulence converts the coarse droplets to fine droplets. This is further stabilised by the addition of emulsifier. The emulsifier also reduces the re-coalescence and maintain the particle size.

Microfluidization is another technique used for the formulation of NEs in which microchannel of size 300 µm is used to reduce the particle size. The pressure involved here is 200 MPa and the flow of emulsion in the microchannel is up to 400 m/s. This high velocity through the narrow diameter generated high shear stress thereby converting the coarse emulsion into NE.

Few methods that produce stable NEs are high pressure homogenization, microfluidization, ultrasonic homogenization and phase inversion have been summarized in Table 3 [118]. NEs have the basic constituents like aqueous phase, oil/organic phase, and an emulsifying agent/surfactant [119] as depicted in Fig. 2. The surfactant usually contributes to only about 1.5 to 10%. The surfactant also helps in altering the electrostatic charge in the NEs [119,120]. In the formulation of NEs, of EOs it as always preferred to have a natural surfactant and stabilizers like protein or polysaccharides although, studies have shown that the effectiveness is compromised due to slow absorption during homogenization. Surfactant mixing techniques are of two types: mixed surfactants (emulsifier in oil and emulsifier in water) and segregated surfactants (emulsifier in corresponding phases). Formulation of O/W NEs are only successful if the process is associated with the transitional phase inversion, three phase emulsion system. In a study solely on the relationship between different formulation methods found that amphiphilic molecules like sodium dodecyl sulphate and Tweens are more successful [121,122], whereas a success story was reported in the usage of modified starch as emulsifying agent in the formulation of clove and peppermint EO based NEs [123,124]. The mechanism of antimicrobial action has been attributed to the property of intercalating the genetic material within the cells, inhibition of Adenosine triphosphate dependent transport across cell membranes, impairment of cell division, cellular death due to toxicity, increased hydroxylation leading to inhibition of metabolic activities, disruption of cell membranes and inhibition of enzymatic activity. Table 4 lists the types of NEs of EOs reported with its antibacterial effects against bacterial
strains [28,125-140]. EOs which already have antimicrobial properties can be formulated into NEs to enhance their properties and better agent efficiency against biofilms and multidrug resistant bacteria. NEs are less complex to formulate and are generally considered as safe ingredients. With the addition of emulsifier, it becomes a very stable nanomaterial and provide great versatility in application. NEs can also encapsulate various antimicrobial agents and properties can be formulated into NEs to enhance their properties and better agent efficiency against biofilms and multidrug resistant bacteria. NEs are less complex to formulate and are generally considered as safe ingredients. With the addition of emulsifier, it becomes a very stable nanomaterial and provide great versatility in application. NEs can also encapsulate various antimicrobial agents and

| Table 3. Formulation techniques of nanoemulsion (NE) |
| --- | --- | --- |
| Formulation techniques | Mode of action | References |
| Phase inversion | Phase inversion is achieved when oil is agitated in water to obtain fine dispersion of interconversion between those two phases, by varying the chemical composition or the temperature keeping either as constant. | [118] |
| Ultrasonication method | Vigorous agitation of regular emulsion by ultrasound renders fine nanodroplets of it. Used mostly for small batch production. | [118] |
| High-pressure homogenizer | High pressure with the help of a homogenizer when applied to the solution contains two separate phases in the presence of surfactants and co emulsifying agents. Though it generates too much heat thus used only for O/W with > 20% oil content. | [118] |
| Micro-fluidization | The coarse emulsion yielded from homogenizer is further refined to form stable NEs using an apparatus which is called a microfluidizer with pressure pump at very high pressure. | [118] |
| High-amplitude ultrasound | Not unlike the ultrasonication method, this is also used for small-batches formulation of NEs. Ultrasonic cavitation generates high shear forces which creates vacuum bubbles and those results in NEs. | [118] |

O/W: oil in water.

| Table 4. Antimicrobial effect of nanoemulsions (NEs) of essential oils (EOs) |
| --- | --- | --- | --- |
| Ne of EOs | Target organism | Antimicrobial activity | References |
| Monolaurin with Tween 20 and Tween 80 and Tween 40 | Staphylococcus aureus, Escherichia coli, | Upto 92% inhibition in diluted NE and undiluted NE led a zero viability of S. aureus and E. coli cells in under 1 min | [28] |
| tri-n-butyl phosphate, soybean oil & with Triton X 100 | Bacillus subtilis, | Complete reduction in planktonic bacterial viability | [125] |
| Thyme oil along soybean oil, with Tween 80 eugenol, cinnamon tree bark oil | E. coli O157:H7, S. aureus, Listeria monocytogenes, Salmonella spp., | 3 log or 99.9% reduction in L. monocytogenes and E. coli O157:H7 | [125,126] |
| Ethyl oleate with Tween 80 | Pseudomonas aeruginosa | Antibacterial effect on planktonic bacterial cells of all tested organisms. 3 log or 99.9% reduction in viable counts of the biofilms | [127] |
| Eugenol with Surlynol 485W | E. coli, Salmonella enterica, | Inhibition of growth of L. monocytogenes for up to 48 h. Viable counts of E. coli reduced bile duct ligation under 60 min | [128] |
| Clove oil with Tween 20 | L. monocytogenes, E. coli O157:H7, P. aeruginosa, Salmonella typhi, L. monocytogenes Proteus mirabilis, S. aureus | Exhibited larger zones of inhibition against Gram-positive strains than Gram-negative strains | [129] |
| Eucalyptus oil with Tween 80 and Tween 20 | L. monocytogenes, E. coli | Showed significant cell wall disintegration | [130] |
| Basil oil with Tween 80 | E. coli | 99.999% reduction in viable counts in under 1 min | [131] |
| Tea tree oil with Tween 80 | S. aureus, S. epidermidis, Propionibacterium acnes, E. coli | Highly efficient in inhibition of tested organisms | [132-134] |
| Sunflower oil with Surfactin | S. aureus, Bacillus circulans, Vibrio parahaemolyticus, E. coli, S. typhi, L. monocytogenes, B. cereus | Increased bactericidal activity against S. typhi, S. aureus, and L. monocytogenes | [135] |
| Cinnamon leaf oil with Tween 80 | B. cereus | Completely bactericidal (99.999%) in 2 h | [136] |
| Black seed oil with Tween 80 | S. aureus, B. cereus, Salmonella typhimurium | Efficient reduction against S. aureus, B. cereus, and S. typhimurium | [137] |
| Soybean oil with cephalosporin C (CPC) | Acinetobacter baumannii | Inhibitive reduction in the number of CFU/mL in the duration of 15 to 60 min | [138] |
| Golden flaxseed oil with Tween 80 | S. aureus | Inhibited biofilm formation | [139] |
| Celery oil and Tween 80 | S. aureus | Demonstrated resistance towards microbial strain interaction | [139,140] |
antivirals and can even mimic various target receptors of microorganism thereby multiplexing the mode of action. The NEs of EO can be further researched as promising candidates for therapeutic, theragnostic applications against the various nosocomial infections arising due to COVID. The future direction leads to the improvement in the precision and reproducibility of the NEs. Advanced methods of fabrication such as 3D printing has also been reported though it is relativity less explored, the concept and potential to control emulsion size and functionalization by using precise nozzles is a very promising technology.

4. Conclusion

EOs represent natural safe and effective alternatives to chemical antibiofilm agents, specifically against those associated with healthcare environments and medical-devices that are susceptible to multi-drug-resistant bacteria. Captivating results and growing interest are seen in the case of NEs formulation of EOs for the efficient combat against nosocomial infections as they offer plenteous benefits like being a natural antibacterial agent with great physicochemical equilibrium stability, and due to its complex composition, it can target various factor and sites in microbial cellular structure, they are also comparatively inexpensive, non-toxic and safe around even kids. Future studies can be carried out to study the exact model of the mechanism of the NEs of EOs and the therapeutic aspect of proper dosage and duration of treatment and safe handling issues. In conclusion, the prospects of NEs of EOs to prevent and inhibit virulence and biofilm formation in planktonic bacteria seems very promising and due to the versatility in the formulation techniques, tailor-made NEs can be implemented for various applications, not just to fight nosocomial infections but also other areas where antimicrobial action is mandated. Amongst the plethora of nanomaterials available, stable NEs of EOs and their bioactive compound as nano bio-coatings is an interesting direction to explore.

Acknowledgements

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1A2C2006888).

Ethical Statements

The authors declare no conflict of interest.

Neither ethical approval nor informed consent was required for this study.

References

1. Cadel-Six, S., E. Cherchame, P. E. Douarre, Y. Tang, A. Felten, P. Barbet, E. Litrip, S. Banerji, S. Simon, F. Pasquali, M. Gourmeton, N. Mensah, M. Borowiak, M. Y. Mistou, and L. Petrovska (2021) The spatiotemporal dynamics and microevolution events that favored the success of the highly clonal multidrug-resistant monophase Salmonella Typhimurium circulating in Europe. Front. Microbiol. 12: 651124.
2. Du, X. H., X. Y. Zhang, X. R. Lin, Q. L. Liu, G. Tao, and P. Lin (2021) [Clinical characteristics and risk factors of nosocomial infection in 472 patients with non-Hodgkin lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 29: 751-756.
3. Karakonstantis, S., E. I. Kritotakas, and A. Gikas (2020) Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options. J. Antimicrob. Chemother. 75: 271-282.
4. Matar, G. M. (2018) Editorial: Pseudomonas and Acinetobacter: from drug resistance to pathogenesis. Front. Cell. Infect. Microbiol. 8: 68.
5. Jee, Y. (2020) WHO International Health Regulations Emergency Committee for the COVID-19 outbreak. Epidemiol. Health. 42: e2020013.
6. Dayanand, M. and S. K. M. Rao (2004) Prevention of hospital acquired infections: a practical guide. Med. J. Armed Forces India. 60: 312.
7. Pichler, K., V. Giordano, G. Tropf, R. Fuiko, A. Berger, and J. Rittenschober-Boehm (2021) Impact of different types of nosocomial infection on the neurodevelopmental outcome of very low birth weight infants. Children (Basel). 8: 207.
8. Sydnor, E. R. and T. M. Perl (2011) Hospital epidemiology and infection control in acute-care settings. Clin. Microbiol. Rev. 24: 141-173.
9. Türe Yüce, Z. and E. Alp (2016) [Infection control bundles for the prevention of hospital infections]. Mediterr. J. Infect. Microbes Antimicrob. 5: 8.
10. Contou, D., R. Cally, P. Desaint, M. Fraissé, and G. Plantevêe (2021) Causes and timing of death in critically ill COVID-19 patients. Crit. Care. 25: 79.
11. Kolpen, M., M. Kühl, T. Bjarnsholt, C. Moser, C. R. Hansen, L. Liengaard, A. Kharazmi, T. Pressler, N. Høiby, and P. O. Jensen (2014) Nitrous oxide production in sputum from cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. PLoS One. 9: e84353.
12. Das, R., S. Sebastian, A. Kapil, and B. Dhowan (2017) Decline of nosocomial methicillin-resistant Staphylococcus aureus skin and soft tissue infections in an Indian tertiary hospital: hope for the future. J. Clin. Diagn. Res. 11: DL01-DL02.
13. Prasad, R., A. K. Jha, and K. Prasad (2018) Exploring the Realms of Nature for Nanosynthesis. Springer International Publishing, Cham, Switzerland.
14. Lázaro-Diez, M., S. Remuzgo-Martínez, C. Rodriguez-Mirones, F. Acosta, J. M. Icardo, L. Martinez-Martinez, and J. Ramos-Vivas (2016) Effects of subinhibitory concentrations of cefaroline on methicillin-resistant Staphylococcus aureus (MRSA) biofilms. PLoS One. 11: e0147569.
15. Dong, G., J. Li, L. Chen, W. Bi, X. Zhang, H. Liu, X. Zhi, T. Zhou, and J. Cao (2019) Effects of sub-minimum inhibitory concentrations of ciprofloxacin on biofilm formation and virulence factors of Escherichia coli. Braz. J. Infect. Dis. 23: 15-21.
Mill essential oils. *J. Gastrointest. Cancer.* 51: 260-266.

50. Mitropoulou, G. H., Bardouki, M. Vamvakias, P. Panas, P. Paraskeas, A. Rangou, and Y. Kourkoutas (2018) Antimicrobial activity of *Pistacia lentiscus* and *Fortunella margarita* essential oils against *Saccharomyces cerevisiae* and *Aspergillus niger* in fruit juice. *J. Biotechnol.* 280 Suppl. S62-S63.

51. Fidan, H., G. Stefanova, I. Kostova, S. Stankov, S. Danyanova, A. Sotyanova, and V. D. Zhelezakov (2019) Chemical composition and antimicrobial activity of *Laurus nobilis* L. essential oils from Bulgaria. *Molecules.* 24: 804.

52. Řebíčková, K., T. Bajer, D. Šilha, K. Ventura, and P. Bajerová (2020) Comparison of chemical composition and biological properties of essential oils obtained by hydrodistillation and steam distillation of *Laurus nobilis L.* Plant Foods Hum. Nutr. 75: 495-504.

53. Leong, W.-H., K.-S. Lai, and S.-H. E. Lim (2021) Combination therapy involving *Lavandula angustifolia* and its derivatives in exhibiting antimicrobial properties and combating antimicrobial resistance: current challenges and future prospects. *Processes (Basel).* 9: 609.

54. Kakar, H., A. Sajjad, S. Rizwan, K. Mahmood, Z. Mehmood, M. Azam, I. Hafeez, A. M. Sarangzai, A. Nadman, and M. Yasinai (2017) Chemical composition, antimicrobial and antileishmanial activity of essential oil of *Juniperus excelsa* M.Bieb. from Ziarat, Balochistan. *Pure Appl. Biol. 6:* 786-796.

55. Muftah, H., B. Ozçelik, O. Oyardi, I. Kultuk, and N. Orhan (2020) A comparative evaluation of *Juniperus* species with antimicrobial magistrates. *Pak. J. Pharm. Sci.* 33: 1443-1449.

56. Linden, L., I. Farias, A. E. Dos Santos, K. Da Silveira, and F. Sampaio (2018) Antimicrobial evaluation of sutures containing *Lippia sidoides* Cham essential oil. *Proceedings of MOL2NET 2018. International Conference on Multidisciplinary Sciences.* 2018 January 15-2019 January 20. Basel, Switzerland.

57. Santana Neto, M. C., M. L. V. D. A. Costa, P. H. D. S. Fialho, G. L. N. Lopes, K. A. Figueiredo, I. M. Pinheiro, S. G. de Lima, R. S. Nunes, P. V. Quelemes, and A. L. M. Carvalho (2020) Development of chlorhexidine digluconate and *Lippia sidoides* essential oil loaded in microemulsion for disinfection of dental root canals: substantivity profile and antimicrobial activity. *AAPS PharmSciTech.* 21: 302.

58. Zerkani, H., I. Tagnaoute, S. Zerkani, F. Radi, S. Amine, A. M'Bieb. from Ziarat, Balochistan. *J. Essent. Oil-Bear. Plants.* 2018 January 15-2019 January 20. Basel, Switzerland.

59. Chouhan, S., K. Sharma, and S. Galeria (2017) Antimicrobial activity of some essential oils-present status and future perspectives. *Medicines (Basel).* 4: 58.

60. Mohammed, T. G. M. and A. F. Abd El-Rahman (2020) Eco-friendly cinnamaldehyde based emulsion for phytopathogenic bacterial growth inhibitor. *J. Adv. Microbiol.* 20: 1-12.

61. Wiatrak, K., T. Morawiec, R. Rój, P. Kownacki, A. Nitecka-Bucha, D. Niedzielski, P. Cholewka, D. Baldi, and A. Mertas (2021) Evaluation of effectiveness of a toothpaste containing tea tree oil and ethanolic extract of propolis on the improvement of oral function status of albino Wistar rats. *Asian Food Sci. J.* 13: 1-7.

62. Purkait, S., A. Bhattacharya, A. Bag, and R. R. Chattopadhyay (2020) Meticulos approach towards pharmacognosy and socio-economic impact of ethnomedicinal plant: *Ocimum kilimandscharicum*. *Res. J. Pharm. Technol.* 13: 4751-4764.

63. Fidow, B., N. Bhabhacharya, A. Bag, and R. R. Chattopadhyay (2020) Synergistic antibacterial, antifungal and antioxidant efficacy of cinnamom and clove essential oils in combination. *Arch. Microbiol.* 202: 1439-1448.

64. Sidde, L., M. Sushma, and B. Jayanthi (2020) Phytochemical and *in-vitro* pharmacological screening of *Ocimum kilimandscharicum* extract. *World J. Curr. Med. Pharm. Res.* 2: 251-257.

65. Nikolić, M. M., K. K. Jovanović, T. L. Marković, D. L. M. Bieb. from Ziarat, Balochistan. *J. Biotechnol.* 9: 609-612.
Abdel-Reheem, M. A. and M. M. Oraby (2015) Anti-microbial, cytotoxicity, and necrotic ripostes of 
Pimpinella anisum essential oil. Ann. Agric. Sci. 60: 335-340.

Ksouda, G., S. Sellimi, F. Merlier, A. Falcimategne-Cordin, B. Thomasset, M. Nasri, and M. Haji (2019) Composition, antibacterial and antioxidant activities of Pimpinella saxifraga essential oil and application to cheese preservation as coating additive. Food Chem. 288: 47-56.

Crevelin, E. J., S. C. Caixeta, H. J. Dias, M. Groppo, W. R. Cunha, C. H. G. Martins, and A. E. M. Crotti (2015) Anti-microbial activity of the essential oil of Plectranthus neochilus against cariogenic bacteria. Evid. Based Complement. Alternat. Med. 2015: 102317.

Thoppil, J. E., A. Tajo, J. Minjia, M. J. Deena, K. Sreeanji, L. Leeja, M. Sivadasan, and A. H. Allfarhan (2014) Antimicrobial activity of the essential oils of three species of Pogostemon. J. Environ. Biol. 35: 795-798.

de Sousa, E. C., A. B. da Silva, K. S. de Melo, I. R. Maldonado, and E. R. Machado (2019) Antimicrobial effect of Rosmarinus officinalis Linn essential oil on pathogenic bacteria in vitro. pp 281-295. In: Y. C. de Souza Salgado (ed.). Patologia: Doencas Bacterianas e Fúngicas. Atena Editora, Ponta Grossa, Brazil.

Badia, V. M. S. R. de Oliveira, G. Polmann, T. Milkievici, A. C. Galvão, and W. da Silva Robazza (2020) Effect of the addition of antimicrobial oregano (Origanum vulgare) and rosemary (Rosmarinus officinalis) essential oils on lactic acid bacteria growth in refrigerated vacuum-packed Tuscan sausage. Braz. J. Microbiol. 51: 289-301.

Kužma, L., D. Kalenba, M. Rózálska, B. Rózálska, M. Wieckowska-Szakiel, U. Krajevska, and H. Wysokitska (2009) Chemical composition and biological activities of essential oil from Salvia scarea plants regenerated in vitro. Molecules. 14: 1438-1447.

Cui, H., X. Zhang, H. Zhou, C. Zhao, and L. Lin (2015) Antimicrobial activity and mechanisms of Salvia scarea essential oil. Bot. Stud. 56: 16.

Farahpour, M. R., E. Pirkehez, A. Ashrafian, and A. Sorboli (2020) Accelerated healing by topical administration of Salvia officinalis essential oil on Pseudomonas aeruginosa and Staphylococcus aureus infected wound model. Biomed. Pharmacother. 128: 110120.

Stojanović-Radić, Z., M. Pejić, N. Stojanović, J. Sharifi-Rad, and L. El-Rhaffari (2014) Biological investigations of antioxidant, antimicrobial properties and chemical composition of essential oil from Warionia saharae. Oxid. Antioxid. Med. Sci. 3: 73-78.

Mandal, S., B. Chatterjee, and B. Layek (2021) Cellulose-based nanomaterials in drug delivery applications. pp. 57-86. In: H. Bera, C. M. Hossain, and S. Saha (eds.). Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications. Academic Press, San Diego, CA, USA.

Shariatini, Z. (2021) Cell penetration peptide-based nanomaterials in drug delivery and biomedical applications. pp. 535-588. In: H. Bera, C. M. Hossain, and S. Saha (eds.). Biopolymer-Based Nanomaterials in Drug Delivery and Biomedical Applications. Academic Press, San Diego, CA, USA.

Qais, F. A., M. S. Khan, and I. Ahmad (2018) Nanoparticles as quorum sensing inhibitor: prospects and limitations. pp. 227-244. In: V. C. Kalia (ed.). Biotechnological Applications of Quorum Sensing Inhibitors. Springer, Singapore.

Wolska, K. I., A. M. Grudniak, and K. Markowska (2017) Inhibition of bacterial quorum sensing systems by metal nanoparticles. pp. 123-138. In: M. Rais and R. Shegokar (eds.). Metal Nanoparticles in Pharma. Springer, Cham, Switzerland.

Qais, F. A., I. Ahmad, M. Altaf, and S. H. Alotaibi (2021) Biofabrication of gold nanoparticles using Capsicum annuum extract and its anti-quorum sensing and antibiofilm activity against bacterial pathogens. ACS Omega. 6: 16670-16682.

Shen, H., Y. Liu, Y. Liu, Z. Duan, P. Wu, Z. Lin, and H. Sun (2021) Hormetic dose-responses for silver antibacterial compounds, quorum sensing inhibitors, and their binary mixtures on bacterial resistance of Escherichia coli. Sci. Total Environ. 786: 147464.
attenuate quorum sensing regulated virulence and biofilm formation in *Pseudomonas aeruginosa* PA01. IET Nanobiotechnol. 12: 1056-1061.

109. Shen, Y., Z. J. Ni, K. Thakur, J. G. Zhang, F. Hu, and Z. J. Wei (2021) Preparation and characterization of clove essential oil loaded nanoemulsion and pickering emulsion activated pullulan-gelatin based edible film. *Int. J. Biol. Macromol.* 181: 528-539.

110. Das, S., K. Vishakha, S. Banerjee, S. Mondal, and A. Ganguli (2020) Sodium alginate-based edible coating containing nanoemulsion of *Citrus sinensis* essential oil eradicates planktonic and sessile cells of food-borne pathogens and increased quality attributes of tomatoes. *Int. J. Biol. Macromol.* 162: 1770-1779.

111. Nirmala, M. J., V. Gopakumar, P. Mahajan, S. Bollapalli, and R. Nagarajan (2018) Nano-scale emulsion system of Tulsi essential oil and its applications. *J. Bionanosci.* 12: 842-848.

112. Jaiswal, M., R. Dudhe, and P. K. Sharma (2015) Nanoemulsion: an advanced mode of drug delivery system. *J. Biotech.* 5: 123-127.

113. Jafari, S. M. and D. J. McClements (2018) Nanoemulsions: Formulation, Applications, and Characterization. Academic Press, San Diego, CA, USA.

114. Karakus, S. (2018) *Science and Technology: Behind Nanoemulsions*. IntechOpen, London, UK.

115. Vauthier, C. and G. Ponchel (2016) Polymer Nanoparticles for Nanomedicines: A Guide for their Design, Preparation and Development. Springer International Publishing, Cham, Switzerland.

116. Li, G., Z. Zhang, H. Liu, and L. Hu (2021) Nanoemulsion-based delivery approaches for nutraceuticals: fabrication, application, characterization, biological fate, possible toxicity and future trends. *Food Funct.* 12: 1933-1953.

117. McClements, D. J. and J. Rao (2011) Food-grade nanoemulsions: an advanced mode of drug delivery system. *J. Biotec.* 5: 123-127.

118. Barradas, T. N. and K. G. de Holanda e Silva (2021) Nanoemulsions of essential oils to improve solubility, stability and permeability: a review. *Environ. Chem. Lett.* 19: 1153-1171.

119. Mustafa, I. F. and M. Z. Hussein (2020) Synthesis and technology of nanoemulsion-based pesticide formulation. *Nanomaterials (Basel).* 10: 1608.

120. Feng, L., B. Cui, D. Yang, C. Wang, Z. Zeng, and Y. Wang, C. Sun, X. Zhao, and H. Cui (2016) Preparation and evaluation of emamectin benzoate solid microemulsion. *J. Nanomater.* 2016: 2386938.

121. Qian, C. and D. J. McClements (2011) Formation of nanoemulsions stabilized by model food-grade emulsifiers using high-pressure homogenization: factors affecting particle size. *Food Hydrocoll.* 25: 1000-1008.

122. Komai, J. and D. J. McClements (2015) Low-energy formation of edible nanoemulsions by spontaneous emulsification: factors influencing particle size. *J. Food Eng.* 146: 122-128.

123. Liang, R., S. Xu, C. F. Shoemaker, Y. Li, F. Zhong, and Q. Huang (2012) Physical and antimicrobial properties of peppermint oil nanoemulsions. *J. Agric. Food Chem.* 60: 7548-7555.

124. Majeed, H., F. Liu, J. Hagebekima, H. R. Sharif, J. Qi, B. Ali, Y. Y. Bia, J. Ma, W. Yokoyama, and F. Zhong (2016) Bactericidal action mechanism of negatively charged food grade clove oil nanoemulsions. *Food Chem.* 197: 75-83.

125. Teixeira, V. H., S. Casal, and M. B. P. Oliveira (2007) PAHs content in sunflower, soybean and virgin olive oils: evaluation in commercial samples and during refining process. *Food Chem.* 104: 106-112.

126. Ma, Q., P. M. Davidson, and Q. Zhong (2016) Antimicrobial properties of microemulsions formulated with essential oils, soybean oil, and Tween 80. *Int. J. Food Microbiol.* 226: 20-25.

127. Hickey, S., S. A. Hagan, E. Kudryashov, and V. Buckin (2010) Analysis of phase diagram and microstructural transitions in an ethyl oleate/water/Tween 80/Span 20 microemulsion system using high-resolution ultrasonic spectroscopy. *Int. J. Pharm.* 388: 213-222.

128. Gaysinsky, S., T. M. Taylor, P. M. Davidson, B. D. Bruce, and J. Weiss (2007) Antimicrobial efficacy of eugenol microemulsions in milk against *Listeria monocytogenes* and *Escherichia coli* O157:H7. *J. Food Prot.* 70: 2631-2637.

129. Yoo, J. H., K. H. Baek, Y. S. Heo, H. I. Yong, and C. Jo (2021) Synergistic bactericidal effect of clove oil and encapsulated atmospheric pressure plasma against *Escherichia coli* O157:H7 and *Staphylococcus aureus* and its mechanism of action. *Food Microbiol.* 93: 103611.

130. Sari, R., M. Muhan, and I. Fajriati (2017) [Antibacterial activity of ethanolic leaves extract of agarwood (*Aquilaria microcarpa* Bail.) against *Staphylococcus aureus* and *Proteus mirabilis*]. *Pharm. Sci. Res.* 4: 143-154.

131. Ghosh, V., A. Mukherjee, and N. Chandrasekaran (2013) Ultrasonic emulsification of food-grade nanoemulsion formulation and evaluation of its bactericidal activity. *Ultras. Sonochem.* 20: 338-344.

132. Najafi-Taher, R., B. Ghaemi, and A. Amani (2018) Delivery of adapalene using a novel topical gel based on tea tree oil nano-emulsion: permeation, antibacterial and safety assessments. *Eur. J. Pharm. Sci.* 120: 142-151.

133. Vo, T. V., Y. Y. Chou, and B. H. Chen (2021) Preparation of microemulsion from an alkyl polyglycoside surfactant and tea tree oil. *Molecules.* 26: 1971.

134. Biju, S. S., A. Ahuja, R. K. Khar, and R. Chaudhry (2005) Formulation and evaluation of an effective pH balanced topical antimicrobial product containing tea tree oil. *Pharmazie.* 60: 208-211.

135. Joe, M. M., K. Bradeeba, R. Parthasarathi, P. K. Sivakumar, P. S. Chauhan, S. Tipayno, A. Benson, and T. Sa (2012) Development of surfactin based nanoemulsion formulation from selected cooking oils: evaluation for antimicrobial activity against selected food associated microorganisms. *J. Taiwan Inst. Chem. Eng.* 43: 172-180.

136. Ghosh, V., S. Saranya, A. Mukherjee, and N. Chandrasekaran (2013) *Cinnamon oil nanoemulsion formulation by ultrasonic emulsification: investigation of its bactericidal activity.* *J. Nanosci. Nanotechnol.* 13: 114-122.

137. Shaaban, H. A., Z. Sadek, A. E. Edris, and A. Saad-Hussein (2015) Analysis and antibacterial activity of *Nigella sativa* essential oil evaluated in microemulsion system. *J. Oleo Sci.* 64: 223-232.

138. Hwang, Y. Y., K. Ramalingam, D. R. Bienek, V. Lee, T. You, and R. Alvarez (2013) Antimicrobial activity of nanoemulsion in combination with cetlypyridinium chloride in multidrug-resistant *Acinetobacter baumanii*. *Antimicrob. Agents Chemother.* 57: 3568-3575.

139. Machado, G. T. P., M. B. Veleirinho, L. A. Honorato, and S. Kuhnhen (2020) Formulation and evaluation of anti-MRSA nanoemulsion loaded with *Achyrocline satureioides*: a new sustainable strategy for the bovine mastitis. *Nano Express.* 1: 030004.

140. Nirmala, M. J., L. Durai, V. Gopakumar, and R. Nagarajan (2020) Preparation of celery essential oil-based nanoemulsion by ultrasonication and evaluation of its potential anticancer and antibacterial activity. *Int. J. Nanomedicine.* 15: 7651-7666.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.